第 四 篇 跨 步 精 進 展 望 未 來
Chapter 4 Future Challenges
115
三、執行醫療科技評估
(
Health
Technology Assessment,
HTA)
依據健保法第
42
條第
2
項規定，醫療
服務給付項目及支付標準之訂定，保險人得
先辦理醫療科技評估，並應考量人體健康、
醫療倫理、醫療成本效益及本保險財務；
藥物給付項目及支付標準之訂定，亦同。
考量新藥、新科技之評估有其時效性，
惟目前評估人力及資源有限，所以，先行
選擇單價較高且對健保財務影響較大之品
項辦理醫療科技評估。目前，執行
HTA
案
件之條件如下：
III. Carrying Out Health Technology Assessments
According to Article 42, Clause 2 of the NHI Act, the
NHIA must conduct a health technology assessment (HTA)
before an item is approved to be covered under the system
and its reimbursement rate is set. The factors considered in
the assessment are the item’s effect on human health, its cost
effectiveness, medical ethics, and the NHI system’s finances.
The same applies in determining whether a drug will be
covered andwhat its reimbursement rate will be.
Time is often urgent when considering new drugs and
new technologies. Because of the limited manpower and
resources the NHIAcan devote to conducting assessments, its
primary HTA targets are usually more costly items that will
have a bigger impact on the NHI system’s finances. For an
item to undergo an HTA, it has to meet certain conditions, as
detailed below: